ReviewCurrent opinion in pharmacology2013
Emerging trends in the discovery of natural product antibacterials.
Review in Current opinion in pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Novel Insights into the Nobilamide Family from a Deep-SeaMarine drugs · 2025Article
- Antioxidant and Antibacterial Activities of Selected Medicinal Plants from Addis Ababa against MDR-Uropathogenic Bacteria.International journal of molecular sciences · 2024Article
- Article
- Heterologously expressed SacP23, a novel bacteriocin fromRoyal Society open science · 2023Article
- Synthesis and Antimicrobial Evaluation of Side-Chain Derivatives based on Eurotiumide A.Marine drugs · 2020Article
- Antibacterial Potential ofInternational journal of microbiology · 2020Article
- Emerging evolutionary paradigms in antibiotic discovery.Journal of industrial microbiology & biotechnology · 2019Review
- The Quest for Novel Antimicrobial Compounds: Emerging Trends in Research, Development, and Technologies.Antibiotics (Basel, Switzerland) · 2019Review
- Synthetic Biology of Natural Products.Cold Spring Harbor perspectives in biology · 2016Review
- Complete Genome Sequence of Streptomyces venezuelae ATCC 15439, Producer of the Methymycin/Pikromycin Family of Macrolide Antibiotics, Using PacBio Technology.Genome announcements · 2016Article
- Antimicrobial Activity of Monoramnholipids Produced by Bacterial Strains Isolated from the Ross Sea (Antarctica).Marine drugs · 2016Article
- Endless Resistance. Endless Antibiotics?MedChemComm · 2016Article
- Synthetic biology advances for pharmaceutical production.Current opinion in biotechnology · 2015Review
- Precise cloning and tandem integration of large polyketide biosynthetic gene cluster using Streptomyces artificial chromosome system.Microbial cell factories · 2015Article
- Whole-genome sequencing targets drug-resistant bacterial infections.Human genomics · 2015Review
- High-Quality Draft Genome Sequence of Actinobacterium Kibdelosporangium sp. MJ126-NF4, Producer of Type II Polyketide Azicemicins, Using Illumina and PacBio Technologies.Genome announcements · 2015Article
- Functional chromatographic technique for natural product isolation.Organic & biomolecular chemistry · 2015Article
- Rational and combinatorial tailoring of bioactive cyclic dipeptides.Frontiers in microbiology · 2015Review
- Article
- Exploring the Anti-Burkholderia cepacia Complex Activity of Essential Oils: A Preliminary Analysis.Evidence-based complementary and alternative medicine : eCAM · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This article highlights current trends and advances in exploiting natural sources for the deployment of novel and potent anti-infective countermeasures. The key challenge is to therapeutically target bacterial pathogens that exhibit a variety of puzzling and evolutionarily complex resistance mechanisms. Special emphasis is given to the strengths, weaknesses, and opportunities in the natural product antibacterial drug discovery arena, and to emerging applications driven by advances in bioinformatics, chemical biology, and synthetic biology in concert with exploiting bacterial phenotypes. These efforts have identified a critical mass of natural product antibacterial lead compounds and discovery technologies with high probability of successful implementation against emerging bacterial pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.